BCG,BCG+IL-2膀胱灌注预防膀胱癌复发的疗效评价

BCG,BCG and IL-2 intravesical instillation in the prevention of postopcrative recurrence of bladder tumor

摘要: 本文对BCG,BCG＋IL－2膀胱灌注预防膀胱癌术后复发的疗效进行了分析,74例膀胱癌分为两组。一组40例单用BCG(150mg),另一组34例BCG(100mg)＋IL－2(20000Iu)。BCG组随访18～72月,平均30.9月,无肿瘤复发率80％(32/40),BCG＋IL－2组随访16～7O月,平均29.4月,无肿瘤复发率88.3％(3O/34),两组比较有显著性(P<0.01)。结果表明,无论单独用BCG或BCG＋IL－2联合应用,疗效都十分肯定,而BCG＋IL－2组更优,可减少BCG用量,毒副反应小。

Abstract: Railway Medical College in Xuzhou, Xuzhou 221009For the prevention of tumor recurrence,intravesical instillation of only 150mg BCGwas instituated postoperatively in 40 cases of bladder cancer and intravesical instillationof a combination of 20000 unites of IL-2 and 100mg of BCG in another 34.In the BCGgroup, 80% (32/40) have been free of tumor for a mean time of 30.9 months (follow upranging from 18 to 72 months) and in the combination of BCG and IL-2 group, 88.3%(30/34) have been free of tumor for a mean time of 29.4% months (follwo up rangingfrom 16 to 70 months).Comparing the results of two groups, it is striking (P<0.01).The results revealed that BCG or combination BCG and IL-2 intravesilal instillation inthe prevention of tumor recurrence, which effect were very definited.The later groupwhat is more dominant, it decreased the dose of BCG and the side-effect minor.